334 related articles for article (PubMed ID: 33115992)
21. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
22. Bicytopenia in Primary Lung Melanoma Treated with Nivolumab.
Takahashi A; Kubo A; Mizuno S; Kasai K; Asai N; Yonezawa T; Kosaka K; Nishimura M; Tanaka H; Yokoe N; Tsuzuki T; Takami A; Yamaguchi E
Intern Med; 2019 Mar; 58(6):827-831. PubMed ID: 30449777
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
[TBL] [Abstract][Full Text] [Related]
24. Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
Sakurai T; Takahashi J; Komatsu T; Mitsumura H; Iguchi Y
Mod Rheumatol Case Rep; 2023 Jun; 7(2):416-421. PubMed ID: 36715286
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report.
Chen YH; Liu FC; Hsu CH; Chian CF
Medicine (Baltimore); 2017 Jul; 96(27):e7350. PubMed ID: 28682883
[TBL] [Abstract][Full Text] [Related]
26. Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma.
Iyer SG; Khakoo NS; Aitcheson G; Perez C
BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32943444
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
Miyauchi M; Toyoda M; Zhang J; Hamada N; Yamawaki T; Tanaka J; Harada K; Kashizaki F; Fukagawa M
J Diabetes Investig; 2020 May; 11(3):748-749. PubMed ID: 31587459
[TBL] [Abstract][Full Text] [Related]
28. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
[TBL] [Abstract][Full Text] [Related]
29. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors.
Ohira J; Kawamoto M; Sugino Y; Kohara N
Medicine (Baltimore); 2020 Apr; 99(15):e19741. PubMed ID: 32282733
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
[TBL] [Abstract][Full Text] [Related]
31. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
[TBL] [Abstract][Full Text] [Related]
32. Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
Sato K; Ono T; Sato F; Kawahara A; Azuma K; Kawaguchi T; Akiba J; Umeno H
Oral Oncol; 2020 Feb; 101():104366. PubMed ID: 31300273
[TBL] [Abstract][Full Text] [Related]
33. Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature.
Matsuo K; Ishiguro T; Najama T; Shimizu Y; Kobayashi Y; Mutou M
Intern Med; 2019 Aug; 58(16):2367-2372. PubMed ID: 31118387
[TBL] [Abstract][Full Text] [Related]
34. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
[TBL] [Abstract][Full Text] [Related]
36. Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature.
Veccia A; Kinspergher S; Grego E; Peterlana D; Berti A; Tranquillini E; Caffo O
Anticancer Drugs; 2020 Jun; 31(5):540-544. PubMed ID: 32011360
[TBL] [Abstract][Full Text] [Related]
37. [An autopsy case of nivolumab-induced myasthenia gravis and myositis].
Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S
Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711
[TBL] [Abstract][Full Text] [Related]
38. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
39. Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review of the Literature.
Manapov F; Roengvoraphoj O; Dantes M; Marschner S; Li M; Eze C
J Immunother; 2018; 41(2):96-99. PubMed ID: 29200082
[TBL] [Abstract][Full Text] [Related]
40. Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases.
Inthasot V; Bruyneel M; Muylle I; Ninane V
Acta Clin Belg; 2020 Aug; 75(4):308-310. PubMed ID: 31179880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]